CN102908624A - 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 - Google Patents

包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 Download PDF

Info

Publication number
CN102908624A
CN102908624A CN2012104520326A CN201210452032A CN102908624A CN 102908624 A CN102908624 A CN 102908624A CN 2012104520326 A CN2012104520326 A CN 2012104520326A CN 201210452032 A CN201210452032 A CN 201210452032A CN 102908624 A CN102908624 A CN 102908624A
Authority
CN
China
Prior art keywords
ethyl
active component
phenyl
bicyclo
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012104520326A
Other languages
English (en)
Chinese (zh)
Inventor
理查德.布尔
罗南.福特
安德鲁.马瑟
安东尼奥.梅特
凯瑟琳.威利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Original Assignee
Pulmagen Therapeutics Synergy Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0808710A external-priority patent/GB0808710D0/en
Priority claimed from GB0900563A external-priority patent/GB0900563D0/en
Application filed by Pulmagen Therapeutics Synergy Ltd, AstraZeneca AB filed Critical Pulmagen Therapeutics Synergy Ltd
Publication of CN102908624A publication Critical patent/CN102908624A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2012104520326A 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 Pending CN102908624A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0808710A GB0808710D0 (en) 2008-05-13 2008-05-13 New combination 296
GB0808710.8 2008-05-13
GB0900563A GB0900563D0 (en) 2009-01-14 2009-01-14 New combination
GB0900563.8 2009-01-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980127403XA Division CN102088976B (zh) 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品

Publications (1)

Publication Number Publication Date
CN102908624A true CN102908624A (zh) 2013-02-06

Family

ID=41318921

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2012104520326A Pending CN102908624A (zh) 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
CN200980127403XA Expired - Fee Related CN102088976B (zh) 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980127403XA Expired - Fee Related CN102088976B (zh) 2008-05-13 2009-05-12 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品

Country Status (11)

Country Link
US (1) US20110190309A1 (enExample)
EP (1) EP2315589A4 (enExample)
JP (1) JP2011520877A (enExample)
KR (1) KR20110010725A (enExample)
CN (2) CN102908624A (enExample)
AU (1) AU2009247021B2 (enExample)
BR (1) BRPI0912657A2 (enExample)
CA (1) CA2723909A1 (enExample)
MX (1) MX2010012019A (enExample)
RU (1) RU2010147881A (enExample)
WO (1) WO2009139708A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EP2300464A1 (en) 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
KR101845257B1 (ko) 2011-02-07 2018-04-04 삼성전자주식회사 이미지 센서
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (enExample) * 1942-12-16
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US6223485B1 (en) * 1996-06-07 2001-05-01 Herman Miller, Inc. Wall panel system
WO1998004517A1 (en) * 1996-07-29 1998-02-05 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
EP1383730A2 (en) * 2001-04-03 2004-01-28 Aryx Therapeutics Anticholinergic compounds and methods of use
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008059239A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702457D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
EP2300464A1 (en) * 2008-05-13 2011-03-30 AstraZeneca AB Quinuclidine derivatives as muscarinic m3 receptor antagonists
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Also Published As

Publication number Publication date
KR20110010725A (ko) 2011-02-07
AU2009247021A1 (en) 2009-11-19
EP2315589A4 (en) 2013-09-11
BRPI0912657A2 (pt) 2016-01-26
JP2011520877A (ja) 2011-07-21
US20110190309A1 (en) 2011-08-04
CA2723909A1 (en) 2009-11-19
WO2009139708A1 (en) 2009-11-19
AU2009247021B2 (en) 2012-06-07
CN102088976B (zh) 2012-12-26
CN102088976A (zh) 2011-06-08
RU2010147881A (ru) 2012-06-20
MX2010012019A (es) 2011-03-04
EP2315589A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
CN101678005B (zh) 毒蕈碱性受体拮抗剂和β-2肾上腺素受体激动剂的组合
JP6823095B2 (ja) 噴霧乾燥製剤
ES2392795T3 (es) Indoles como moduladores del receptor nicotínico de acetilcolina de subtipo alfa-7
ES2892954T3 (es) Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos
JP2024045124A (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
US10207998B2 (en) Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
TWI665178B (zh) 作為化療劑的β－取代的β－氨基酸和類似物及其應用
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
JP6437119B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
CA2895448A1 (en) Autotaxin inhibitors
CN103012378A (zh) 作为5-ht2a血清素受体调节剂适用于治疗与其相关的病症的3-苯基-吡唑衍生物
TW201000103A (en) Combinations comprising methotrexate and DHODH inhibitors
TW200843750A (en) New combination 665
CN102131505A (zh) 用于调节β2-肾上腺素受体活性的包含4-羟基-2-氧代-2，3-二氢-1，3-苯并噻唑-7-基化合物的药物组合物
CN109476635A (zh) 用于治疗疾病的二取代吡唑类化合物
UA127760C2 (uk) Кристалічна тверда форма солі n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-фторфеніл)циклопропан-1,1-дикарбоксаміду (варіанти), спосіб отримання та метод використання
CN102908624A (zh) 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
KR20240136361A (ko) 약학적 건조 분말 흡입 제제
US11767298B2 (en) Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
CN102202664A (zh) 包含毒蕈碱性受体拮抗剂和β2肾上腺素受体激动剂的药物产品
JP2005516891A (ja) アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
WO2025119390A1 (zh) P2x7受体拮抗剂
CN109476638A (zh) 吡唑衍生物、其组合物及治疗用途
CN109071457A (zh) 吲哚胺2,3-双加氧酶的抑制剂
JP2019517476A (ja) Ｅａａｔ３阻害剤としてのピラゾール化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130206